CTI BioPharma Corp. (CTIC)

0.92
NASDAQ : Health Technology
Prev Close 0.89
Day Low/High 0.86 / 0.92
52 Wk Low/High 0.60 / 2.30
Avg Volume 241.80K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 51.34M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

First Week of CTIC January 2016 Options Trading

First Week of CTIC January 2016 Options Trading

Investors in Cell Therapeutics, Inc. saw new options become available this week, for the January 2016 expiration.

Cell Therapeutics (CTIC) Highlighted As Today's Perilous Reversal Stock

Cell Therapeutics (CTIC) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a "perilous reversal" (up big yesterday but down big today) candidate

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.

Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week

Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week

The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.

The J.P. Morgan Healthcare Confab Monday Morning News Dump

The J.P. Morgan Healthcare Confab Monday Morning News Dump

It's still pre-dawn in San Francisco, a few hours from the start of the J.P. Morgan Healthcare Conference, but that hasn't stopped biotech and drug companies from dumping a ton of news and announcements into the market. Here's a brief look at what's making headlines this morning:

Time to Analyze Small-Caps Again

These three carry nice valuations.

Heavy Early Morning Activity On Cell Therapeutics (CTIC)

Heavy Early Morning Activity On Cell Therapeutics (CTIC)

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a pre-market mover with heavy volume candidate

Http://www.celltherapeutics.com/

Http://www.celltherapeutics.com/

Baxter International Inc. (NYSE:BAX) and Cell Therapeutics, Inc.

Deal Or No Deal: Hedge Funds Like These 6 Small Cap Stocks Under 5 Dollars

Deal Or No Deal: Hedge Funds Like These 6 Small Cap Stocks Under 5 Dollars

James Dennin, Kapitall: We decided to look for small cap stocks under 5 dollars that may benefit from just the [...]

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Interesting CTIC Put And Call Options For June 2014

Interesting CTIC Put And Call Options For June 2014

Investors in Cell Therapeutics, Inc. saw new options begin trading this week, for the June 2014 expiration.

Cell Therapeutics Must Deliver on Promise for Myelofibrosis Drug Partner

Cell Therapeutics Must Deliver on Promise for Myelofibrosis Drug Partner

Cell Therapeutics's shares are rising on the promise made by CEO Jim Bianco to land a pacritinib partner by year's end.

First Week Of November 16th Options Trading For Cell Therapeutics (CTIC)

First Week Of November 16th Options Trading For Cell Therapeutics (CTIC)

Investors in Cell Therapeutics, Inc. saw new options begin trading this week, for the November 16th expiration.

The Horrific Destruction of Biotech Shareholder Value In One Simple Chart

The Horrific Destruction of Biotech Shareholder Value In One Simple Chart

Cell Therapeutics has lost 99.99 percent of its value in the last dozen years.

Cell Therapeutics: Addicted to Reverse Stock Splits

Cell Therapeutics: Addicted to Reverse Stock Splits

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.

The Worst Biotech CEO of 2012 Is...

The Worst Biotech CEO of 2012 Is...

Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Readers get to decide which of the CEOs from BioSante, BioCryst, Peregrine or Cell Therapeutics deserve the dishonor.

Genta: 1998-2012

Genta: 1998-2012

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

More data will help Peregrine convince skeptics that bavituximab is a real lung cancer drug.

Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)

Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)

Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)

2012 Biotech Stock Predictions: An Interim Report Card

2012 Biotech Stock Predictions: An Interim Report Card

Check out the accuracy of the 2012 biotech sector predictions made by Adam Feuerstein

Cell Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Cell Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Cell Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript

Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course

Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course

The purchase of another cancer drug is another excuse to raise more money and to pay lavish executive salaries.

The 5 Dumbest Things on Wall Street This Week: Feb. 3

The 5 Dumbest Things on Wall Street This Week: Feb. 3

David Bests Bruce; Bianco's Bunk; RadioShack's Reflections; STOCK Act Silliness; Cali's Latest Crisis.

Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances

Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances

Cell Therapeutics suffers another drug development setback and hurts shareholders yet again.

Play TheStreet's FDA Drug-Approval Contest

Play TheStreet's FDA Drug-Approval Contest

The FDA will issue approval decisions on 17 drugs over the next four months. How well can you predict which drugs will be approved or rejected?

5 Under-$10 Stocks Set to Soar

5 Under-$10 Stocks Set to Soar

These volatile stocks could pay off big in the near term.

The Worst Biotech CEO of 2011 Is ...

The Worst Biotech CEO of 2011 Is ...

TheStreet's readers tagged this biotech chief executive with the 'worst' title, topping four other nominees.

TheStreet Quant Rating: D (Sell)